Synshark LLC
- UEI
- JN79BGB2MD84
- CAGE
- 6ZRK5
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Website
- synshark.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Soligenix, Inc. | Princeton, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Synshark LLC is a company that specializes in producing and supplying high-quality terpene oils for the cosmetic and medical sectors. Their flagship product is Tobacco Squalene, which is used as an adjuvant in vaccines to enhance the immune response. Synshark is registered as a for-profit, veteran-owned, service-disabled veteran-owned limited liability company.
Through prime federal grant awards from agencies like the National Institutes of Health (NIH) and U.S. Department of Agriculture (USDA), Synshark has received over $1.2 million to support research and development of plant-based, sustainable sources of squalene as a natural adjuvant for vaccines. A major $514,006 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) at NIH is funding efforts to engineer tobacco plants to accumulate squalene on their leaves, providing a renewable source for this adjuvant currently derived from shark liver oil. Additional USDA grants totaling $750,000 have supported earlier stage development of high squalene tobacco. Synshark has collaborated with North Carolina State University on this plant metabolic engineering work applicable to vaccine adjuvant manufacturing. The squalene research aligns with federal programs like the NIAID Vaccine Research Program and Adjuvant Research initiatives aimed at improving vaccine efficacy and pandemic preparedness.
Quick answers
Is Synshark LLC registered in SAM.gov?
Synshark LLC's SAM.gov registration expired on January 13, 2025.
What is Synshark LLC's most recent federal award?
Synshark LLC's most recent federal grant award is Tobacco-based sustainable squalene for novel vaccine adjuvant emulsions (R43AI172710), from National Institute of Allergy and Infectious Diseases (NIH), on August 15, 2022.
On GovTribe
See Synshark LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors